StreetAlpha.app
Home › Stocks › NRSN

NeuroSense Therapeutics Ltd. (NRSN)

$1.53
▼ −3.77%
LAST CLOSE · NOV 17

NeuroSense Therapeutics develops drug candidates for neurodegenerative diseases, led by PrimeC for ALS. It last closed at $1.53 on Nov 17, down 3.77% on the day. NRSN last reported earnings on Tue, Jun 30, 2026.

AI Auto Pilots
Is NRSN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$11.1M
Free cash flow
−$7.7M
Balance sheet
Cash & equivalents
$166K
At Dec 31
Shareholder equity
−$1.6M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$3.2M−$3.2MFY2021FY2022: −$10.5M−$10.5MFY2022FY2023: −$10.1M−$10.1MFY2023FY2024: −$10.2M−$10.2MFY2024FY2025: −$11.1M−$11.1MFY2025

From NRSN's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 31). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Last report
Jun 30
2026 · Time not announced
Reported EPS
$0.00
vs -$0.11 est. · beat
Year-ago EPS
-$0.19
Same quarter last year
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated NRSN in the past 90 days, not enough for a consensus
Average 12-month target
$52.00
▲ 3298.7% upside

Based on 1 analyst who set a price target on NRSN in the past 90 days. The average target is $52.00, with a high of $52.00 and a low of $52.00, compared with the last close of $1.53.

Low $52.00Avg $52.00High $52.00
Blue marker: last close $1.53
Highest target$52.00
Average target$52.00
Lowest target$52.00
Latest rating changes
HC Wainwright & Co.Target raised
Sep 28Buy$8 → $52
HC Wainwright & Co.Initiated
Sep 3Buy$8
DateFirmActionRatingPrice target
Sep 28HC Wainwright & Co.Target raisedBuy$8 → $52
Sep 3HC Wainwright & Co.InitiatedBuy$8
Loading…

Technical Analysis

NRSN · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 25% below its 20 day and 150% below its 50 day average. It is 673% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the Pivot S1 at $1.50, and the nearest resistance the Pivot R1 at $1.56.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 22.3%/day
Key levels
$25.4052 week high+1560.1%
$11.83200 day average+673.2%
$7.37100 day average+381.7%
$3.8350 day average+150.3%
$2.08Swing high (Nov 11)+35.9%
$1.9120 day average+24.8%
$1.56Pivot R1+2.0%
$1.53Pivot+0.0%
$1.53Last close
$1.50Pivot S1−2.0%
$1.2752 week low−17.0%
$1.27Swing low (Nov 3)−17.0%
Indicators
RSI (14)28.68Oversold below 30Oversold
MACD-0.62Above its signal lineBullish
Stochastic29.7Middle of its rangeNeutral
ADX (14)45.4Strong downtrend
Williams %R-75.2Oversold below −80, overbought above −20Neutral
CCI (20)-74.2Oversold below −100, overbought above 100Neutral
Rate of change+15.5%Change over 10 sessionsBullish
ATR (14)$0.34Typical daily range, 22.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NRSN

What happened before

See how NRSN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow NRSN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NRSN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in NRSN in the last 90 days.

Loading…

See today’s whale options flow across the market →

NRSN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼5 buying vs 12 selling
  • ▼Shares held by funds -99.3%
  • ▼Funds holding -7
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding512−58.3%
In funds' top 1000–
Held by funds–––
New / increased5 / 02 / 2+25.0%
Reduced / sold out0 / 122 / 3+140.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NRSN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NRSN is in one of them and how their past NRSN trades turned out.

NRSN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NRSN in an article yet. Here's the latest on the wider market.

NRSN Congress Trades

All congress trades →
Trades, 12 months
1
Buys
1
100%
Sells
0
0%
People
1
Last filed Nov 18
Who traded NRSN · since 2025
Latest 2 filings
$1K – $15KTraded Aug 1, 2025Filed Nov 18, 2025
$1K – $15KTraded May 13, 2025Filed Jul 15, 2025
PersonTypeAmountTradedFiledDelay
Lee ZeldinExecutive branchBuy$1K – $15KAug 1, 2025Nov 18, 2025109 d
Lee ZeldinExecutive branchSell$1K – $15KMay 13, 2025Jul 15, 202563 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About NeuroSense Therapeutics

NeuroSense Therapeutics is a biotechnology company based in Herzliya, Israel, that develops treatments for neurodegenerative diseases such as ALS, Alzheimer's disease and Parkinson's disease. Its lead candidate, PrimeC, is an oral combination of two drugs already approved by the FDA, ciprofloxacin and celecoxib, and it is being developed for people living with ALS. The company is seeking regulatory approval for PrimeC, and its intended users are patients and the healthcare systems that treat them.

Headquarters
Herzliya, Israel